Background: The incidence of testicular germ cell tumors (TGCT) has been increasing in many western countries
for several decades. For 2013, about 7900 new TGCT cases with 370 deaths are estimated in the United States.
While the overall prognosis in metastatic TGCT is excellent, treatment options for patients (pts) relapsing with
cisplaIn-refractory disease are limited. A personalized approach to therapy based upon molecular diagnostic
tools to predict response to specific therapeutic agents may help pts in whom standard chemotherapy has failed